Abstract
The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Current HIV Research
Title: The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication
Volume: 5 Issue: 4
Author(s): Peter Bergman, Lilian Walter-Jallow, Kristina Broliden, Birgitta Agerberth and Johan Soderlund
Affiliation:
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Abstract: The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Export Options
About this article
Cite this article as:
Peter Bergman , Lilian Walter-Jallow , Kristina Broliden , Birgitta Agerberth and Johan Soderlund , The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication, Current HIV Research 2007; 5 (4) . https://dx.doi.org/10.2174/157016207781023947
DOI https://dx.doi.org/10.2174/157016207781023947 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design New Synthetic Vitamin D Analogs with Antiproliferative Activities
Current Pharmaceutical Design Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Dehydroepiandrosterone Delays LDL Oxidation In Vitro and Attenuates Several oxLDL-Induced Inflammatory Responses in Endothelial Cells
Inflammation & Allergy - Drug Targets (Discontinued) An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Thiazolidine: A Potent Candidate for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry A QSAR Study on Some Series of Sodium and Potassium Channel Blockers
Medicinal Chemistry Synthesis of Apoptotic New Quinazolinone-Based Compound and Identification of its Underlying Mitochondrial Signalling Pathway in Breast Cancer Cells
Current Pharmaceutical Design Ion Channels as Medicinal Targets of Biological Toxins: The Impact of Automated Patch-Clamp Electrophysiology
Current Topics in Medicinal Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Matrix Metalloproteinases
Current Medicinal Chemistry A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Preface
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research New Chemical and Biological Aspects of S-Nitrosothiols
Current Medicinal Chemistry